key: cord-0926615-7kztsahf
authors: Rahman, Shakilur; Das, Amit Kumar
title: Integrated Multi-omics, Virtual Screening and Molecular Docking Analysis of Methicillin-Resistant Staphylococcus aureus USA300 for the Identification of Potential Therapeutic Targets: An In-Silico Approach
date: 2021-09-17
journal: Int J Pept Res Ther
DOI: 10.1007/s10989-021-10287-9
sha: fb86fada8b379cb4cdd8320239e7f60bc6084bf4
doc_id: 926615
cord_uid: 7kztsahf

Staphylococcus aureus infection is a leading cause of mortality and morbidity in community, hospital and live-stock sectors, especially with the widespread emergence of methicillin-resistant S. aureus (MRSA) strains. To identify new drug molecules to treat MRSA patients, we have undertaken to search essential proteins that are indispensable for their survival but non-homologous to human host proteins. The current study utilizes a subtractive genome and proteome approach to screen the possible therapeutic targets against S. aureus USA300. Bacterial essential genes are obtained from the DEG database and are compared to avoid cross-reactivity with human host genes. In silico analysis shows 198 proteins that may be considered as therapeutic candidates. Depending on their sub-cellular localization, proteins are grouped as either vaccine or drug targets or both. Extracellular proteins such as cell division proteins (Q2FZ91, Q2FZ95), penicillin-binding proteins (Q2FZ94, Q2FYI0) of the bacterial cell wall, phosphoglucomutase (Q2FE11) and lipoteichoic acid synthase (Q2FIS2) are considered as vaccine targets, and their epitopes have been mapped. Altogether, 53 drug targets are identified, which have shown similarity with the drug targets available in the DrugBank database. Predicted drug targets belong to the common metabolic pathways of MRSA, such as fatty acid biosynthesis, folate biosynthesis, peptidoglycan biosynthesis, ribosome, etc. Protein–protein interaction analysis emphasizing peptidoglycan biosynthesis reveals the connection between penicillin-binding proteins, mur-family proteins and FemXAB proteins. In this study, staphylococcal FemA protein (P0A0A5) is subjected to structure-based virtual screening for the drug repurposing approach. There are 20 residues missing in the crystal structure of FemA, and 12 of these residues are located at the catalytic site. The missing residues are modelled, and stereochemistry is checked. FDA approved drugs available in the DrugBank database have been used in virtual screening with FemA in search of potential repurposed molecules. This approach provides us with 10 drugs that may be used in the treatment of methicillin-resistant staphylococcal mediated diseases. AutoDock 4.2 is used for in silico screening and shows a comparable inhibition constant (Ki) for all 10 FDA-approved drugs towards FemA. Most of these drugs are used in the treatment of various cancers, migraines and leukaemia. Protein–drug interaction analysis shows that the drugs mostly interact with hydrophobic residues of FemA. Moreover, Tyr328 and Lys383 contribute largely to hydrogen bondings during interactions. All interacting amino acids that bind to the drugs are part of the active site cavity of FemA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10989-021-10287-9.

Staphylococcus aureus is a catalase-positive, facultative anaerobic bacterium responsible for causing a wide variety of pus-forming infections of the skin in humans (Carleton et al. 2004 ). S. aureus secretes a bunch of superantigens into blood called enterotoxins, thereby causing food poisoning, toxic shock syndrome, etc. (Lina et al. 2004; Diekema et al. 2001) . S. aureus primarily colonizes in anterior nares of the nose, skins, guts and intestinal tracts (Kluytmans et al. 1997; Sibbald et al. 2006) . Up to 30% of the human population is the relentless carrier of S. aureus in our society (Peacock et al. 2001) . Pathogenicity islands of S. aureus express adhesin and coagulase that causes host blood clotting, thereby making the bacteria resistant to phagocytic killing (Ko et al. 2013) . Besides, S. aureus also produces hyaluronidase and lipases that are actively involved in drug resistance (Ibberson et al. 2014; Cadieux et al. 2014 ).

Among the drug-resistant strains, Methicillin-resistant Staphylococcus aureus (MRSA) has been included in the global priority list of antibiotic-resistant bacteria by the World Health Organization (WHO), considering the high mortality and morbidity associated with invasive infections. MRSA became more threatening when it started showing resistance to multiple antibiotics, including penicillin, oxacillin, amoxicillin, quinolones, macrolides, cephalosporins, tetracycline and chloramphenicol (Chopra and Roberts 2001; Weese and van Duijkeren 2010) . Despite the diversity, ~ 70% of MRSA isolates belong to the major five sequence types (STs: ST22, ST8, ST5, ST239 and ST398) (Giulieri et al. 2020) . Nowadays, half of the S. aureus strains have become methicillin-resistant. Methicillin-susceptible S. aureus (MSSA) acquired the methicillin-resistant gene mecA by a mobile genetic element staphylococcus cassette chromosome (SCC) during the horizontal gene transfer and gave rise to the MRSA (Ito et al. 1999) . The SCC element carries the mecA designated as SCCmec, integrated into the chromosome of MRSA strains (Ito et al. 2001) , and thirteen variants of SCCmec can be found to date (Kaya et al. 2018) . It was immediately discovered that methicillin resistance is different from penicillin resistance in the MRSA phenotype as it does not involve direct inactivation of the antibiotics. Instead, the alternative penicillin-binding protein (PBP2a), a membrane-associated protein, interacts with β-lactam drugs and brings about resistance (Otero et al. 2013) .

One of the Methicillin-resistant Staphylococcus aureus strains, USA300, first emerged in the late 1990s as a community-associated MRSA (CA-MRSA) in the USA (Diekema et al. 2014) . USA300 evolved from a less virulent and less resistant ancestor circulating in Central Europe around 160 years ago (Strauß et al. 2017) . Over time, it became a significant cause of skin and soft-tissue infections and added an overall burden to the MRSA disease (Talan et al. 2011; Moran et al. 2006) . Also, for its virulence, USA300 has emerged as a major cause of healthcare-associated (HA) infections (Jenkins et al. 2009 ). Recently an outbreak of MRSA USA300 among HIV patients has been observed in Japan (Ikeuchi et al. 2021) . Classical USA300 clone belongs to ST8 type and is characterized by specific genetic features like possession of SCCmecIV, Panton-Valentine leucocidin (PVL) and the arginine catabolic mobile element (ACME) (Planet et al. 2013) . Although pulse-field-gel-electrophoresis (PFGE) patterns initially defined USA300, S. aureus USA300 strain gave rise to several variants worldwide over the years (Laupland et al. 2008; Simor et al. 2010; Alvarez et al. 2006; Rajan et al. 2015; Takadama et al. 2020) . USA300_TCH1516 represents the hypervirulent strain of USA300 lineage from the ST8 group of MRSA (Coe et al. 2019) .

Methicillin-resistant S. aureus is a threat to humankind. Despite all the clinical significance, there is a lack of readily available vaccines in the market against the S. aureus bacteria. This bacterium expresses an extensive array of virulence factors such that a vaccine against any one of them may not be sufficient. Though there are many drugs available, but most of them are becoming ineffective with time. Hence it is required to find new drugs which may be used to treat infections caused by methicillin-resistant S. aureus. In this study, genomics and proteomics data of 14 virulent strains of Staphylococcus aureus have been used to understand their genetic features by an integrated interface for computational identification and visualization of genomic islands. Further, the metabolic pathway information of community-acquired methicillin-resistant S. aureus USA300_TCH1516 (KEGG organism: sax) strain is curated from Kyoto Encyclopaedia of Genes and Genomes (KEGG) in search of unique and common pathways between pathogen and host. Non-homologous essential proteins from the pathogen are screened against the DrugBank database for drug repurposing. These proteins have been docked with 1918 FDA-approved drugs obtained from the DrugBank database. This study presents the first approach to predict potential drug and vaccine targets for methicillin-resistant S. aureus USA300, applying the comprehensive subtractive genomics and proteomics computational approach (Fig. 1 ). . To understand the existence and positions of the virulent factors in these 14 genomes, the genomic visualization of these curated virulence factors was performed using IslandViewer 4: an integrated interface for computational identification and visualization of genomic islands (http:// www. patho genom ics. sfu. ca/ islan dview er/) (Bertelli et al. 2017) . NCBI blastn (Johnson et al. 2008 ) was performed to check the percentage of genomic similarity of the other 13 pathogenic strains with USA300_TCH1516 of S. aureus.

In search of unique and common pathways between pathogen and host, metabolic pathway information of community-acquired methicillin-resistant S. aureus USA300_ TCH1516 (KEGG organism: sax) strain was curated from the Kyoto Encyclopedia of Genes and Genomes (KEGG; https:// www. kegg. jp/) (Kanehisa et al. 2021 ) and manually compared with the human (KEGG organism: hsa) metabolic pathways. Information of proteins involved in both the unique and common pathways was extracted from the UniProt (Proteome ID: UP000000793) (https:// www. Fig. 1 The schematic workflow of subtractive genome proteome analysis for predicting potential therapeutic targets for Staphylococcus aureus USA300. This study involves four steps, including Pre-screening, where genome, proteome data of S. aureus USA300_TCH1516 was retrieved from various databases followed by Screening. Bacterial essential proteins are checked for non-homologous to the human host, and subcellular localization analysis was performed in the Screening step. In the next step, B-cell epitopes were predicted for the extracellular proteins, and drug targets are identified from the pool of bacterial essential non-homologous proteins by searching in the DrugBank database for which the experimental evidence of binding with proteins similar to the target proteins are available. The final step involves the Structurebased drug designing and drug repurposing approach for an essential non-homologous protein selected based on proteinprotein interaction analysis unipr ot. org/) (Bateman 2019) 

Database of essential genes (DEG; http:// origin. tubic. org/ deg/ public/ index. php/ index) contains genomic information from bacteria, archaea and eukaryotic organisms necessary for maintaining their lives (Luo et al. 2014) . Currently, 30,878 essential bacterial genes are present in the database (Updated on 1st September 2020). To identify the essential proteins of the MRSA USA300_TCH1516 strain, the BLASTP analysis that is integrated with the DEG database, was performed. Proteins with e-value < 0.0001 and bit score > 100 were considered as essential proteins for bacteria (Jadhav et al. 2013 ).

Host proteins were avoided to circumvent side effects while searching for possible therapeutic targets. Initially, the metabolic pathway information of the host and pathogen were collected and compared manually. To determine the nonhomologous genes, protein sequences were subjected to NCBI BLASTp server (https:// blast. ncbi. nlm. nih. gov/ Blast. cgi) (Boratyn et al. 2012) . A similarity search of S. aureus essential genes was performed against the human proteome. Proteins with e-value < 0.005 and sequence similarity < 35% (Pearson 1995 (Pearson , 1996 were considered as non-homologous to the human host. This analysis is an essential determining step since it helps to avoid cross-reactivity with the host proteome for designing vaccines and drugs (Sarkar et al. 2012 ).

In general, extracellular, periplasmic and surface proteins are treated as potential vaccine targets. Additionally, the inner membrane and cytoplasmic proteins are considered as drug targets (Solanki et al. 2019) . Therefore, subcellular localization screening was performed for all the resultant target proteins using PSORTb v3.0 server (https:// www. psort. org/ psortb/) (Yu et al. 2010 ) and CELLO v2.5 server (http:// cello. life. nctu. edu. tw/) (Yu et al. 2006) . Predicted extracellular proteins were further cross-verified for their transmembrane domain using TMHMM v2.0 server (http:// www. cbs. dtu. dk/ servi ces/ TMHMM/) (Moller et al. 2001) . The extracellular and surface-expressed proteins so obtained were further subjected to antigenicity checking.

Validating immunogenic protein targets is essential before vaccine designing. The VaxiJen v2.0 server (http:// www. ddg-pharm fac. net/ vaxij en/ VaxiJ en/ VaxiJ en. html) was used for computationally predicting the potential of a protein to induce antigenicity in the host where the threshold value was set to 0.4 (Doytchinova and Flower 2007) . The target proteins with a higher value above the threshold limit were considered as immunogenic. The resultant antigenic proteins were then subjected to epitope mapping.

Proteins obtained from VaxiJen v2.0 were analysed for linear B-cell epitope prediction. In general, peptide vaccines are better than whole organisms or large proteins because peptide fragments confer a highly targeted immune response and avoid unnecessary antigenic load. Peptide vaccine only includes antigenic epitope despite using the complete antigen protein (Li et al. 2014) . Epitope identification is a costly and time-consuming process as it requires experimental screening of large datasets of potential epitope candidates. The B-cell epitope is a linear peptide fragment of the antigen that binds to the immunoglobulin or antibody (Sanchez-Trincado et al. 2017 ). B-cells recognize solventexposed antigens through the B-cell receptors (Jespersen et al. 2019) . Protein sequences of vaccine targets were used to predict B-cell epitopes using, artificial neural networkbased ABCpred server (http:// crdd. osdd. net/ ragha va/ abcpr ed/) (Saha and Raghava 2006) , and three-dimensional structure-based BepiPred 2.0 server (http:// www. cbs. dtu. dk/ servi ces/ BepiP red/) (Jespersen et al. 2017 ) and IEDB antibody epitope prediction server (http:// tools. iedb. org/ main/ bcell/) (Vita et al. 2019) with an epitope threshold setting of 0.51. The most common epitopes from the three servers were then selected as vaccine targets.

The most reliable way to identify the druggability of proteins is to identify the similar proteins which can bind to the druglike compound (Hajduk et al. 2005) . Non-homologous essential proteins were searched against the DrugBank database to find out the FDA-approved drugs in the DrugBank database (https:// go. drugb ank. com/) (Wishart et al. 2018 ) using the inbuilt BLAST tool. Druggability analysis was performed for all the essential non-homologous protein targets with default search parameters (e-value < 0.00001). DrugBank database contains a comprehensive molecular information about drugs, their mechanisms, their interactions and their targets. Based on this, hits found with DrugBank were considered as druggable targets with FDA-approved drugs, whereas others were considered as novel drug targets.

Peptidoglycan is the main component of S. aureus cell wall, a complex, three-dimensional mesh surrounding the entire cell (Vollmer et al. 2008) . It maintains the cell shape, integrity and protects the bacteria; thereby, the biosynthetic machinery of peptidoglycan has been a preferred target for the discovery of antibacterials (Nikolaidis et al. 2014 ). To understand the involvement of proteins towards peptidoglycan biosynthesis, protein-protein interaction (PPI) studies were performed. Thus, the essential non-homologous proteins that were obtained from the previous analysis were accounted for PPI studies, and the peptidoglycan synthesis pathway was analysed further. This study provides information about their potential roles in metabolic, biological and functional aspects. Search Tool for the Retrieval of Interacting Genes/Proteins (STRING v11.0) (https:// string-db. org/) (Szklarczyk et al. 2019) was used for mapping the interactions between non-homologous target proteins to create an intra-species protein-protein interaction network.

Drug resistance is governed by genomic factors that are involved in cell wall metabolism (Berger-Bächi and Tschierske 1998); thereby, this study focused on targeting cell-wall biosynthesis proteins. Studies show that Staphylococcal FemXAB family proteins play a vital role in the later stages of peptidoglycan biosynthesis and may serve as suitable targets for therapeutic agents (Monteiro et al. 2019 ). Structurebased virtual screening requires the crystal structure of the target protein. The crystal structure of the staphylococcal FemA protein was retrieved from the Protein Data Bank (https:// www. rcsb. org/) (Goodsell et al. 2020 ) under code 1LRZ (Benson et al. 2002) . The missing residues 209-220 and 413-420 of FemA were fixed by Robetta (Kim et al. 2004 ), phyre2 (Kelley et al. 2015) and SWISS-MODEL (Waterhouse et al. 2018 ). The quality of the model structures was validated using QMEAN (Qualitative Model Energy ANalysis) (https:// swiss model. expasy. org/ qmean/) (Benkert et al. 2011) , prosa (https:// prosa. servi ces. came. sbg. ac. at/ prosa. php) (Wiederstein and Sippl 2007) and PROCHECK (Laskowski et al. 1993 ). The best model was optimized by 200 steps steepest descent energy minimization using the Swiss-PdbViewer (Guex et al. 2009 ).

The active site of FemA was analysed and screened for drug identification (Benson et al. 2002) . The receptor structure was prepared for virtual screening by adding the polar hydrogen atoms and Kollman charges. One thousand nine hundred and eighteen FDA-approved drugs were downloaded in SDF file format from DrugBank Database for screening. No ligand-bound FemA crystal structure is available in Protein Data Bank (PDB). So, it was necessary to proceed with the active site pocket for virtual screening. During ligand preparation, the prepareligand4.py python script supplied by the Auto-Dock developers (Morris et al. 2009 ), was used. Open Babel was used to convert all drug compound files into PDBQT format (O'Boyle et al. 2011) . A receptor grid-box was generated with grid box dimensions of 90 Å × 90 Å × 90 Å with centre at x = 42.075, y = 62.493, z = 90.597. AutoDock Vina (Trott and Olson 2009 ) was used for virtual screening of processed drugs against S. aureus FemA. Further, the top ten drugs obtained from the virtual screening were accounted for docking analysis using AutoDock 4.2 (Morris et al. 2009 ).

The receptor was subjected to pre-processing to be used in AutoDock 4.2 (Morris et al. 2009 ) for docking. Polar hydrogens followed by Kollman charges were added to FemA. Non-polar hydrogens were merged, and Gasteiger charges were added to the selected ligands using AutoDock 4.2. The same gridbox with a centre at x = 42.075, y = 62.493, z = 90.597 and dimensions of 90 Å × 90 Å × 90 Å with a grid space of 0.375 was used for molecular docking using the AutoDock 4.2 tool, which was earlier used in virtualscreening. Lamarckian Genetic Algorithm (GA) was used to perform a total of 10 runs. Autodock estimates free energy of binding (∆G), which is the sum of the intermolecular energy (vdW + H-bond + desolv Energy + Electrostatic Energy), the internal energy, and the torsional energy minus the unbound system's internal energy (Morris et al. 2008) . AutoDock calculates the inhibition constant (Ki) value using the equation [Ki = exp(∆G/(R*T)]. The final result of docking was visualized by UCSF Chimera v1.15 (Pettersen et al. 2004) , and the structures were analyzed manually by LigPlot + (Laskowski and Swindells 2011) to decrypt the receptor-ligand interactions.

S. aureus USA300_TCH1516 strain (NC_010079) had a circular genome of ~ 2.87 Mbp (Supplementary Fig. 1 ) with ~ 32.7% GC content also contained 2,763 coding genes (Supplementary Table 1 ). The genome size of 14 strains ranged between 2.7 and 2.9 Mbp, and their GC content varied between 32.7 and 32.9% (Supplementary Table 1 ). IslandViewer4 presented the respective positions of curated virulence factors, homologs of virulence factors, curated resistance genes, homologs of resistance genes in S. aureus USA300_TCH1516 based on codon usage, dinucleotide bias and phylogenetically related genome information. Genome island visualization of all fourteen strains was in the supplementary document ( Supplementary Fig. 1 ).

The KEGG database contained 337 metabolic pathways from human and 105 metabolic pathways from S. aureus USA300_TCH1516. Out of the 105 metabolic pathways, 29 pathways were found to be unique to S. aureus USA300_ TCH1516 (Supplementary Table 2) , and the remaining 76 pathways were shared by both pathogen and host (Supplementary Table 3 ).

Out of the 295 essential proteins present in the DEG database, 198 essential proteins were identified as non-homologous to the host, thereby defined as "NON-HOST" (Supplementary Table 4 ). Essential proteins possess a significant role in the pathogenicity and survival of the organism (Lewin et al. 2019) . So, these 198 essential non-homologous proteins are very crucial for S. aureus-mediated pathogenesis. These proteins can be exploited as potential therapeutic candidates.

Sub-cellular localization of protein plays a vital role in understanding the protein function, providing breakthrough information for drug designing and discovery. A total of 190 cytoplasmic and inner membrane proteins were identified as drug targets, and eight extracellular proteins were identified as potential vaccine targets (Supplementary Table 4 ).

Antigenicity is the ability to be recognized explicitly by the antibodies generated due to the immune response to the given substance (Ilinskaya and Dobrovolskaia 2016) . VaxiJen v2.0 provided the antigenicity information of the epitopes to understand the immunomodulatory effect of epitopes that were identified from immunogenic regions. Epitopes with a higher than VaxiJen cut-off value (0.4) were selected as potential epitopes, and their antigenicity values range from 0.5 to 0.8 (Supplementary Table 5 ). Out of 8 extracellular proteins, seven proteins except Diadenylate cyclase (Q2FW92) meet the threshold value (> 0.4), and possess antigenicity ( Table 2 ).

A total of seven antigenic extracellular proteins were identified from the bacterial membrane of S. aureus USA300_ TCH1516. Two cell division proteins (Q2FZ91, Q2FZ95), two penicillin-binding proteins (Q2FZ94, Q2FYI0) of bacterial cell wall, pentose phosphate pathway component phosphoglucomutase (Q2FE11), glycerolipid metabolism pathway component lipoteichoic acid synthase (Q2FIS2) and an uncharacterized protein; are the vaccine targets onto which B-cell epitopes were mapped (Table 1) . Predicted epitopes fall into the solvent-accessible part of the proteins recognized by respective antibodies (Jespersen et al. 2019 ). Here, five anticipated epitopes are the mixtures of secondary structures such as helix and coil (cell division protein DivIB, penicillin-binding protein-1 and phosphoglucomutase), β-sheet and coil (penicillin-binding protein-2). However, lipoteichoic acid synthase epitope lies only in coil structure, and cell division protein ftsL lies only in a helical structure. At most penicillin-binding protein-2 and lipoteichoic acid synthase crystal structures are available in Protein DataBank with PDB ID: 3DWK and 2W5Q, respectively.

available drug targets in the DrugBank database provided 53 prioritized drug targets within the USA300_TCH1516 proteome (Table 2) . FDA-approved drugs for which the experimental evidence of binding with proteins similar to S. aureus was available in the DrugBank database. All these prioritized targets belonged to the common metabolic pathways of MRSA, such as fatty acid biosynthesis (Q93QD4, A8Z088, Q6GI75), folate biosynthesis (Q2FY51, Q2G0Q7, Q2FXR9), peptidoglycan biosynthesis (Q2FZ94, Q2FYI0, A8Z4Y6, A8Z012), and ribosome (Q2FEP5, A8YZP4, A8Z2N6, A8YZN7), etc.

Cellular and molecular life depends on a complex network of interactions between the biomolecules. Among these interactions, protein-protein associations are fundamental due to their versatility, specificity and adaptability. Resultant 198 essential non-homologous proteins generated a complex interaction network for S. aureus USA300_TCH1516 proteins ( Supplementary Fig. 2) . This study was emphasized on proteins involved with antibiotic resistance, thereby the peptidoglycan biosynthesis protein cluster was exclusively analysed (Fig. 2) . In this network, it was found that penicillin-binding protein 2 (pbp2) was interacting with the staphylococcal FemA (P0A0A5), FemB (P0A0A8) and the FemX (Q2FEM9). Pbp2 (Q2FYI0) was also found to be interacting with murB to murG, mraY and ddl proteins in the multi-node network. Ddl and Mur family proteins are crucial for peptidoglycan synthesis, thereby found interacting with pbpA (Q2FZ94), another penicillin-binding protein encoded by the pbpA gene. Protein pbp2 was indirectly involved in Biological processes (GO) cell division (GO: 0051301) and cell cycle mechanisms (GO: 0007049). Mur family proteins participated in the peptidoglycan biosynthesis process (GO: 0009252), regulation of cell shape (GO: 0008360), and cell wall organization (GO: 0071555). The mraY (A8Z3M3) and ddl (A8Z4Y6) proteins were crucial players of the peptidoglycan biosynthesis pathway (00550) and the vancomycin resistance pathway (01502). Both pbp2 and pbpA proteins manifested a combined role in peptidoglycan biosynthesis (00550) and β-lactam resistance (01501).

Phyre2 used a one-to-one threading approach, whereas Robetta utilized comparative modelling using the crystal structure of FemA (PDB: 1LRZ). The best structure was provided from each server based on their scoring function. Each structure was checked for its reliability based on QMEAN score, Prosa Z-score and Ramachandran plot analysis. A more positive QMEAN score indicated a better model after evaluating the quality of a protein model. Prosa evaluated the model structure quality by scanning and comparing them Table 6 ).

Top ten hits were obtained from virtual screening based on their binding energies to the receptor (Fig. 3) . All drugs had binding energy of more than − 11.0 kcal/mol (Table 3) . These repurposing drugs are used to treat a wide range of diseases such as hyponatremia, migraine headaches and many types of cancers; Irinotecan in colorectal cancer (Fujita et al. 2015) , Conivaptan in hyponatremia (Ghali 2009 ), Dutasteride in benign prostatic hyperplasia (Wu and Kapoor 2013) , Midostaurin in acute myeloid leukaemia (Fischer et al. 2010) , Rupatadine in symptomatic relief (Keam and Plosker 2007) , Ergotamine, Rimegepant and Dihydroergotamine in migraine (Tfelt-Hansen 2000; Lipton et al. 2019; Schürks 2009 ) and Antrafenine as an anti-inflammatory (Berry et al. 1983 ).

AutoDock 4.2 generates a bunch of energy values (binding energy, ligand efficiency; inhibition constant; intermolecular energy; Van der Waals, electrostatic and total internal energy) using a Lamarckian program. The binding energy and inhibition constant (Ki) indicate the overall strength of a given predicted interaction calculated by AutoDock 4.2 (Matossian et al. 2014) . Molecular docking furnished further insights into the ligand-receptor interactions by providing information about the binding affinity as well as inhibition constant (Ki) for all 10 FDA-approved drugs. Docking results were analyzed to comprehend their interaction with amino acids using LigPlot + (Table 4) . Structure-based virtual screening and docking were attempted focusing on the pocket of 1B domain of staphylococcal FemA that is the only active site according to the literature (Benson et al. 2002) . While analyzing the affinity of drugs for the receptor, it was found that Irinotecan possesses binding (Table 3) . Usually, the smaller the inhibition constant (Ki) value corresponds to a more significant binding affinity, and interestingly Irinotecan also manifests the lowest inhibition constant (Ki). Besides, the highest number of hydrophobic interactions and the formation 

of four hydrogen bonds (H-bond), implying Gly330, Thr332, Ser342 and Gln346 between drug-receptor, probably justified the higher binding energy among all the predicted drugs ( Figs. 4a and 5a) . Dexamethasone metasulfobenzoate showed the second-highest binding energy, i.e., − 10.75 kcal/mol, with a lower inhibition constant value ( Figs. 6f and  7f) , which is the lowest among all. Visual analysis of docked complexes displayed that Phe149, Tyr327, Tyr328, Phe363, Tyr364 and Lys383 are the most common amino acids that show interactions with most of the drugs (10, 10, 10, 9, 10 and 9 drugs respectively) and followed by Ala329, Gly330 and Gly365 (8, 7 and 7 drugs respectively). Besides, Tyr328 and Lys383 showed the highest hydrogen bond interactions. Out of 10 drugs, 7 drug molecules possessed binding energy of more than − 10.0 kcal/mol (Table 3 ). All interacting amino acids binding to the drugs were found to be accumulated in the active site cavity. It was observed that the lower the Ki concentration, the higher the binding energy towards the receptor. And low-affinity binding (high Ki level) implied that a relatively high ligand concentration was required for interaction. Besides, hydrophobic interactions were abundant in the ligand-receptor binding, and all hydrophobic residues were part of domain 1B, the only active site of FemA.

Several significant variants of CA-MRSA in the spatial and temporal population structures distributed globally with different clones dominate different regions globally. But USA300, a multi-locus sequencing (MLST) sequence type (ST) 8-MRSA-IV strain, is relentlessly found worldwide. The CA-MRSA clone ST8 increases virulence in the animal model and clinical incidents of several diseases (Chua et al. 2014) . Even in vitro studies showed increased cytotoxicity of these clones against human macrophages (Laabei et al. 2015) . Staphylococcus aureus is very notorious for its ability to become resistant to antibiotics. Unfortunately, very few antibiotics have been introduced in the past 30 years representing novel chemical classes (Silver 2011 ). The resistance rates of S. aureus and multidrug-resistant strains are increasing gradually, making the clinical anti-infective treatment more difficult. The prospects for badly-needed new drugs to combat against staphylococcal bacteremia with novel mechanisms of action need to be assessed. For broader success, vaccine coverage is crucial to interrupt disease transmission. Virulent factors and essential proteins of S. aureus USA300_TCH1516 and USA300_FPR3757 of USA300 lineage are reported to date. USA300_TCH1516 isotype represents the hypervirulent strain of MRSA USA300 lineage (Coe et al. 2019) . Understanding the evolutionary relationships among pathogenic genomes is vital to target the virulent factors of the methicillin-resistant S. aureus. BLASTn analysis shows that the genomic similarity among all these strains ranges between 98 and 100% (Table 1 ). USA300_ TCH1516 possesses 2920 genes and 2763 proteins though S. aureus JH1 hosts the highest number of genes and proteins (2957 genes, 2808 proteins) among all pathogenic S. aureus strains. Besides, the RF122 strain possesses the smallest gene size, genes and proteins during comparison, but interestingly RF122 contains the highest number of pseudogenes (Supplementary Table 1 ). This study identifies 29 unique pathways such as streptomycin biosynthesis, peptidoglycan biosynthesis, β-lactam resistance, vancomycin resistance, two-component system and quorum sensing etc. Other than that, 76 common pathways are also identified, which are shared by USA300_TCH1516 strain and human. It is well known that essential proteins possess a significant role in the pathogenicity and survival of the organism (Lewin et al. 2019) . Hence, the objective of this study lies in finding out the essential genes of pathogenic S. aureus that have significant dissimilarity with the human genome. The DEG database contains information about 295 essential pathogenic genes for the S. aureus USA300_TCH1516 strain. Avoiding the cross-reactivity of potential therapeutics against human proteins is highly preferred. Upon sequence alignment of 295 essential proteins with the human proteome, 198 pathogenic proteins have been identified that are non-homologous to the host (Supplementary Table 2 ). Several cell division proteins, ribosomal proteins, uncharacterized proteins, cellwall biosynthesis proteins and proteins associated with DNA replication are recognized by this study. Among these, only WalR (A8YYU1), a transcriptional regulatory protein, belongs to the unique metabolic pathway (Two-component system; sax02020), thereby all other essential non-homologous proteins share common metabolic pathways with the human. All these essential non-host proteins are appraised as potential therapeutic targets towards an antibiotic approach.

This work focuses on identifying potential drug targets along with immunogenic vaccine targets. Sub-cellular localization of protein plays a significant role in understanding the protein functions essential for therapeutics discovery and development (Caragea et al. 2010) . Extracellular, periplasmic and surface proteins are considered potential vaccine targets, whereas inner membrane and cytoplasmic proteins are considered drug targets (Solanki et al. 2019) . Several bacterial systems are recently targeted for epitope mapping with this approach (Ain et al. 2018; Hizbullah et al. 2018; Ehsan et al. 2018) . In this context, the sub-cellular localization study defines 175 cytoplasmic proteins, 15 inner membrane proteins and 8 extracellular proteins (Supplementary Table 2 ). Vaccine development requires the prediction of the B-cell epitope, the antigen portion that binds to the antibody. With that purpose, immunogenicity verification of B-cell epitopes is the first stage in vaccine design and development (Zaharieva et al. 2019) . Out of 8 extracellular proteins, 7 proteins except for Diadenylate cyclase (Q2FW92) meet the threshold value (> 0.4), and hence they possess antigenicity (Supplementary Table 5 ). Usually, B-cell epitope length varies from 5 to 20 amino acids. Predicted epitopes have the length ranging from 9 to 16 residues, and fall in the exposed region of extracellular proteins, which are the main criteria for being considered as epitopes. The cell division proteins (Q2FZ91, Q2FZ95), penicillin-binding proteins (Q2FZ94, Q2FYI0) of bacterial cell wall, pentose phosphate pathway component phosphoglucomutase (Q2FE11), and glycerolipid metabolism pathway component lipoteichoic acid synthase (Q2FIS2) are essential for the survival of the pathogen and thereby predicted to have B-cell epitopes in this study. Penicillinbinding proteins (Q2FZ94, Q2FYI0) are involved in the peptidoglycan biosynthesis and β-Lactam resistance and metabolic pathways. Phosphoglucomutase (Q2FE11) is found present in glycolysis, purine metabolism, pentose phosphate pathway and metabolic pathways etc. It is observed that the majority of these proteins (Penicillin-binding proteins, phosphoglucomutase and lipoteichoic acid synthase) are important players of metabolic pathways. However, pathway information is not available for cell division protein FtsL (Q2FZ95) and an uncharacterized protein (Q2G0R4). Phosphoglucomutase and penicillin-binding proteins have been considered as potential vaccine targets in other bacterial systems (Buchanan et al. 2005; Rashid et al. 2017; Shah et al. 2021) . Although immunoinformatics approaches were established to identify potential epitopes from the pathogens, some computationally predicted epitopes may not be optimally immunogenic in vivo. Therefore, the requisition is to test the predicted epitopes to ensure that they can generate B-cell responses.

The druggability of each non-host essential protein of S. aureus USA300_TCH1516 is identified by sequence similarity to the targets of FDA-approved drugs using the Drug-Bank database. This approach reduces the testable proteins to 53 and delivers a list of FDA-approved drugs from the DrugBank that can bind to the target proteins of the pathogen. However, the protein sequence similarity search has limitations in such a way that it does not assure the binding regions identicalness of the identified similar proteins. Thereby, predicted targets are further needed to be validated through clinical experiments. Many specific drug targets that are identified from the common metabolic pathways like cysteine desulfurase (Q2FZY5), D-alanine-D-alanineligase (A8Z4Y6), Malonyl CoA-acyl carrier protein transacylase (Q93QD4), Dihydropteroate synthase, Dihydrofolate reductase (Q2G0Q7), Glutamine synthetase (P0A040), ABC transporter, and Penicillin-binding proteins, ribosomal proteins, etc. It is seen that some of these proteins have been targeted in several other pathogenic bacteria to overcome survivability and drug resistance (Giordano et al. 2018; Prosser and de Carvalho 2013; Zhang et al. 2007; Liu et al. 2006; Kumar et al. 2018; Rehberg et al. 2019; Levy et al. 2008; He et al. 2020; Cui et al. 2019) . So, targeting these essential non-host proteins in MRSA USA300 may pave the way to discovering new potential antibacterial therapeutics that can compromise the survivability of the drug-resistant S. aureus.

The clusters of peptidoglycan biosynthesis render a brief idea about the proteins responsible for antibiotic resistance. Peptidoglycan is the major heteropolymer of the bacterial cell wall that consists of alternate units of N-acetylglucosamine (GlcNAc) and N-acetylmuramoyl-peptides (Mur-NAc-peptide), thereby plays an essential role to protect the bacteria, maintaining characteristic cell shape and many more. Biosynthesis of cell-wall peptidoglycan starts with the formation of UDP-GlcNAc from fructose-6-phosphate, followed by the formation of UDP-MurNAc-pentapeptide from UDP-GlcNAc. In this study, Penicillin-binding protein Pbp2 and PbpA are identified interacting with femXAB family protein, mur-family proteins, Ddl and MraY etc. These bacterial essential proteins are always considered potential therapeutic targets for their cellular importance. MRSA strains have acquired a non-native penicillin-binding protein (PBP2a) which cross-links the peptidoglycan when the native staphylococcal PBPs are occupied by β-lactam antibiotics (Srisuknimit et al. 2017) . Although the activity of mecA gene-encoded Pbp2a origins β-lactam resistance, recent observation shows that resistance can also be mediated by penicillin-binding protein 4 (PBP4) (Alexander et al. 2018) . Thereby all the PBPs can be considered as potential targets against MRSA. The femA protein (P0A0A5) is essential for expressing high-level methicillin resistance in S. aureus (Maidhof et al. 1991; Fri et al. 2020) . Three proteins of the femXAB family, FemX, FemA and FemB, catalyzes sequential addition of glycine residues from glycyl-t-RNAs to the muropeptid, thereby developing the methicillin-resistance (Berger-Bächi and Tschierske 1998; Berger-Bächi 1999) . The absence of functional femXAB proteins lead to improper cell-wall synthesis and increased susceptibility to β-lactam antibiotics (Rohrer et al. 1999; Kopp et al. 1996; Henze et al. 1993) . MraY is a bacterial inner membrane protein essential for cell wall synthesis and targeted in antibiotic research studies (Hering et al. 2018) . Recently, mur-family proteins are chosen as the prioritized drug targets from Acinetobacter baumannii (Amera et al. 2020) . Methicillin resistance is a complex phenomenon and involves all the aforementioned proteins. It is seen that bacterial cell wall synthesis proteins directly or indirectly interacting with penicillin-binding proteins have a significant role in maintaining the cell-wall integrity and antibiotics resistance. So, targeting cell-wall synthesis proteins will give insights into bacterial antimicrobial research.

In this study, staphylococcal FemA (factors essential for methicillin-resistance A) protein accounts for structurebased virtual screening involving the drug repurposing approach due to its immense value in peptidoglycan biosynthesis as discussed earlier. The presence of FemA protein in other S. aureus pathogenic variants is checked using the default BLASTp search function of the DEG database. The search result shows that other than USA300_TCH1516, FemA also exists as an essential protein in MW2, MSSA476 and NCTC 8325 strains of Staphylococcus aureus. FemA crystal structure lacks several residues in its 1B domain, the only active site. This may be due to the binding of the disaccharide hexapeptide lipid substrate (Benson et al. 2002) . Thereby the active site is fixed using the modelling approach. Repurposing of drugs is a strategy for identifying new uses of approved or investigational old drugs. This strategy is advantageous due to the low risk of failure, reduced time frame for drug development and cost-effectiveness (Pushpakom et al. 2019) . The drug repurposing approach successfully provides drugs for the treatment of AIDS, erectile dysfunction, rheumatoid arthritis, breast cancer, colorectal cancer and many more (Clouser et al. 2010; Ghofrani et al. 2006; Edwards et al. 2004; Sporn et al. 2004; Kune et al. 1988) . Several reports tell about the success story of drug repurposing strategy. Recently, repurposing drugs that have been identified through in silico studies, are being used in the treatment of various diseases such as the ZIKA virus (Santos et al. 2020) , SARS-CoV-2 (Zhang et al. 2020) , malaria (Diallo et al. 2021) etc. These studies show that drug molecules are docked using AutoDock software and further experimentally checked with in vitro studies. Auto-Dock is an improved tool to provide accurate binding mode predictions (Trott and Olson 2009) . In this study, docking analysis shows that identified FDA-approved drugs interact with the FemA protein with binding energies ranging between − 7 and − 11 kcal/mol. Irinotecan shows the highest binding affinity (− 11.58 kcal/mol) towards staphylococcal femA with the Ki value of 3.23 nM, engaging the highest number of hydrophobic interactions and four H-bonds. And Antrafenine holds the lowest binding energy (− 7.36 kcal/ mol) with the Ki value of 4050 nM, where only two H-bonds are present with less hydrophobic interactions. In general, hydrogen bonding increases the affinity of drugs towards their target. Besides, An increase in the number of hydrophobic atoms in the active core of the drug-protein interface increases the biological activity of the drug molecule (Patil et al. 2010 ). This defines the critical role of hydrophobic interactions in drug designing and development.Recent studies report that hydrogen bonds and hydrophobic interactions togetherly play an important role in drug-target interactions with an approach to drug-repurposing (Choudhary et al. 2020; Chowdhury et al. 2020) . Dexamethasone, Irinotecan, and Conivaptan are the drugs that show four hydrogen bonds each, though all drug molecules possess hydrogen bond interactions. Irinotecan, Midostaurin and Dihydroergotecan display the maximum number of hydrophobic interactions in the docked structure. In this study, molecular docking analysis reveals that the combinations of hydrogen bonds and hydrophobic interactions are the acting forces in drug-protein interaction; a significantly higher number of hydrophobic interactions are present over there. Interestingly, all hydrophobic residues are part of domain 1B, the catalytic site of FemA protein. Developing new drugs demands time and money thereby, this is always a challenge for the global pharmaceutical industry. So, there is an urgent demand to think differently to lower the investment and time to deliver a new drug to society, and this drug repurposing strategy has it all.

In this study, some novel therapeutic targets for S. aureus USA300 have been identified using in silico approach. These target proteins play a pivotal role in bacterial survival, infection establishment and pathogenesis. Cell-wall synthesis components are used to maintain structural integrity along with antibiotics resistance. Seven membrane proteins with prodigious immunogenic potential were screened as vaccine candidates. These prioritized targets include cell division proteins (Q2FZ91, Q2FZ95), penicillin-binding proteins (Q2FZ94, Q2FYI0) of bacterial cell wall, pentose phosphate pathway component phosphoglucomutase (Q2FE11) and glycerolipid metabolism pathway component lipoteichoic acid synthase (Q2FIS2). A total of 53 potential drug targets are identified, which have shown similarity with the drug targets available in the DrugBank database. Altogether, 198 bacterial essential non-homologous proteins are identified that could be subjected to therapeutics development to be used to combat S. aureus mediated bacteremia. All the peptidoglycan biosynthesis enzymes are essential and specific, therefore provide attractive potential targets for discovering and developing new antibacterials. Due to its biological importance, staphylococcal FemA has been considered an important therapeutic target. The structure-based virtual screening reveals ten potential repurposing drugs to target FemA. Predicted drugs require experimental validation that would lead to the development of new antimicrobial agents in this drug-resistance world.

The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s10989-021-10287-9.

Subtractive proteomics and immunoinformatics revealed novel B-cell derived T-cell epitopes against Yersinia enterocolitica: an etiological agent of Yersiniosis

Structural and kinetic analyses of penicillin-binding protein 4 (PBP4)-mediated antibiotic resistance in Staphylococcus aureus

Community-associated methicillin-resistant Staphylococcus aureus

Prioritization of Mur family drug targets against A. baumannii and identification of their homologous proteins through molecular phylogeny, primary sequence, and structural analysis

UniProt: a worldwide hub of protein knowledge

Toward the estimation of the absolute quality of individual protein structure models

X-ray crystal structure of Staphylococcus aureus FemA

Genetic basis of methicillin resistance in Staphylococcus aureus

Role of fem factors in methicillin resistance

Antrafenine, naproxen and placebo in osteoarthritis: a comparative study

IslandViewer 4: expanded prediction of genomic islands for larger-scale datasets

Domain enhanced lookup time accelerated BLAST

Streptococcus iniae phosphoglucomutase is a virulence factor and a target for vaccine development

Role of lipase from community-associated methicillin-resistant Staphylococcus aureus strain USA300 in hydrolyzing triglycerides into growth-inhibitory free fatty acids

Semi-supervised prediction of protein subcellular localization using abstraction augmented Markov models

Community-adapted methicillin-resistant Staphylococcus aureus (MRSA): population dynamics of an expanding community reservoir of MRSA

Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance

Identification of SARS-CoV-2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach

Drug repurposing approach against novel coronavirus disease (COVID-19) through virtual screening targeting SARS-CoV-2 main protease

Hyperexpression of α-hemolysin explains enhanced virulence of sequence type 93 community-associated methicillin-resistant Staphylococcus aureus

Exploiting drug repositioning for discovery of a novel HIV combination therapy

Multi-strain Tn-Seq reveals common daptomycin resistance determinants in Staphylococcus aureus

Discovery of potential anti-infective therapy targeting glutamine synthetase in Staphylococcus xylosus

Potential repurposing of four FDA approved compounds with antiplasmodial activity identified through proteome scale computational drug discovery and in vitro assay

Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY antimicrobial surveillance program

Continued emergence of USA300 methicillin-resistant Staphylococcus aureus in the United States: results from a nationwide surveillance study

VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

Proteome-wide identification of epitope-based vaccine candidates against multi-drug resistant Proteus mirabilis

Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3

Antibiotic resistance and virulence gene characteristics of methicillin-resistant Staphylococcus aureus (MRSA) isolated from healthy edible marine fish

Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer

Conivaptan and its role in the treatment of hyponatremia

Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond

Cysteine desulfurase IscS2 plays a role in oxygen resistance in Clostridium difficile

Using genomics to understand methicillin-and vancomycin-resistant Staphylococcus aureus infections

RCSB Protein Data Bank: enabling biomedical research and drug discovery

Automated comparative protein structure modeling with SWISS-MODEL and Swiss-Pdb-Viewer: a historical perspective

Predicting protein druggability

Dihydrofolate reductase inhibitors for use as antimicrobial agents

Influence of femB on methicillin resistance and peptidoglycan metabolism in Staphylococcus aureus

Structural basis for selective inhibition of antibacterial target MraY, a membranebound enzyme involved in peptidoglycan synthesis

Reverse vaccinology and subtractive genomics-based putative vaccine targets identification for Burkholderia pseudomallei

Staphylococcus aureus hyaluronidase is a CodY-regulated virulence factor

An outbreak of USA300 methicillin-resistant Staphylococcus aureus among people with HIV in Japan

Understanding the immunogenicity and antigenicity of nanomaterials: past, present and future

Cloning and nucleotide sequence determination of the entire mec DNA of pre-methicillin-resistant Staphylococcus aureus N315

Structural comparison of three types of Staphylococcal Cassette Chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus

Clostridium-DTDB: s comprehensive database for potential drug targets of Clostridium difficile

Epidemiology of healthcare-associated bloodstream infection caused by USA300 strains of methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals

BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes

Antibody specific B-cell epitope predictions: leveraging information from antibody-antigen protein complexes

NCBI BLAST: a better web interface

KEGG: integrating viruses and cellular organisms

SCCmecFinder, a web-based tool for typing of Staphylococcal Cassette Chromosome mec in Staphylococcus aureus using whole-genome sequence data. mSphere

The Phyre2 web portal for protein modeling, prediction and analysis

Protein structure prediction and analysis using the Robetta server

Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks

Phagocytosis escape by a Staphylococcus aureus protein that connects complement and coagulation proteins at the bacterial surface

Staphylococcal peptidoglycan interpeptide bridge biosynthesis: a novel antistaphylococcal target?

Biophysical and in silico interaction studies of aporphine alkaloids with Malonyl-CoA: ACP transacylase (FabD) from drug resistant Moraxella catarrhalis

Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study

Evolutionary trade-offs underlie the multi-faceted virulence of Staphylococcus aureus

LigPlot+: multiple ligand-protein interaction diagrams for drug discovery

PRO-CHECK: a program to check the stereochemical quality of protein structures

Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary

Dihydropteroate synthase from Streptococcus pneumoniae: structure, ligand recognition and mechanism of sulfonamide resistance

Largescale identification of pathogen essential genes during coinfection with sympatric and allopatric microbes

Peptide vaccine: progress and challenges

Standard nomenclature for the superantigens expressed by Staphylococcus

Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine

Characterization and inhibitor discovery of one novel malonyl-CoA: acyl carrier protein transacylase (MCAT) from Helicobacter pylori

VFDB 2019: a comparative pathogenomic platform with an interactive web interface

DEG 10, an update of the database of essential genes that includes both proteincoding genes and noncoding genomic elements: table 1

femA, which encodes a factor essential for expression of methicillin resistance, affects glycine content of peptidoglycan in methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains

In silico modeling of the molecular interactions of antacid medication with the endothelium: novel therapeutic implications in head and neck carcinomas

Evaluation of methods for the prediction of membrane spanning regions

The pentaglycine bridges of Staphylococcus aureus peptidoglycan are essential for cell integrity

Methicillin-resistant S. aureus infections among patients in the emergency department

Using AutoDock for ligandreceptor docking

AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility

Resistance to antibiotics targeted to the bacterial cell wall

Open babel: an open chemical toolbox

Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation

How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function

Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing

What determines nasal carriage of Staphylococcus aureus?

Comparison of methods for searching protein sequence databases

Effective protein sequence comparison

UCSF Chimera-a visualization system for exploratory research and analysis

Emergence of the epidemic methicillin-resistant Staphylococcus aureus strain USA300 coincides with horizontal transfer of the arginine catabolic mobile element and speG-mediated adaptations for survival on skin

Metabolomics reveal D-alanine:D-alanine ligase as the target of D-cycloserine in Mycobacterium tuberculosis

Drug repurposing: progress, challenges and recommendations

Genotyping of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA) in a tertiary care centre in Mysore, South India: ST2371-SCCmec IV emerges as the major clone

Prediction of vaccine candidates against Pseudomonas aeruginosa: an integrated genomics and proteomics approach

3-O -methyl-alkylgallates inhibit fatty acid desaturation in Mycobacterium tuberculosis

The essential Staphylococcus aureus gene fmhB is involved in the first step of peptidoglycan pentaglycine interpeptide formation

Prediction of continuous B-cell epitopes in an antigen using recurrent neural network

Fundamentals and methods for T-and B-cell epitope prediction

Identification of Zika virus NS2B-NS3 protease inhibitors by structure-based virtual screening and drug repurposing approaches

In silico quest for putative drug targets in Helicobacter pylori HPAG1: molecular modeling of candidate enzymes from lipopolysaccharide biosynthesis pathway

Dihydroergotamine: role in the treatment of migraine

Delineating novel therapeutic drug and vaccine targets for Staphylococcus cornubiensis NW1T through computational analysis

Challenges of antibacterial discovery

Methicillin-resistant Staphylococcus aureus colonization or infection in Canada: national surveillance and changing epidemiology

Prioritization of potential vaccine targets using comparative proteomics and designing of the chimeric multi-epitope vaccine against Pseudomonas aeruginosa

Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action

Peptidoglycan cross-linking preferences of Staphylococcus aureus penicillin-binding proteins have implications for treating MRSA infections

Origin, evolution, and global transmission of communityacquired Staphylococcus aureus ST8

STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

A novel community-acquired MRSA clone, USA300-LV/J, uniquely evolved in Japan

Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients

Ergotamine in the acute treatment of migraine: a review and European consensus

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

The Immune Epitope Database (IEDB): 2018 update

Peptidoglycan structure and architecture

SWISS-MODEL: homology modelling of protein structures and complexes

Methicillin-resistant Staphylococcus aureus and Staphylococcus pseudintermedius in veterinary medicine

ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins

DrugBank 50: a major update to the DrugBank database

Dutasteride for the treatment of benign prostatic hyperplasia

Prediction of protein subcellular localization

0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes

VaxiJen dataset of bacterial immunogens: an update

Malonyl-CoA: acyl carrier protein transacylase from Helicobacter pylori: crystal structure and its interaction with acyl carrier protein

A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro